Indiana University-Purdue University Indianapolis (IUPUI) / Understanding β-cell development and function is essential for generating more effective treatment options for individuals with diabetes. A key player in pancreatogenesis, islet development, and mature β-cell function is the Pdx1 transcription factor (TF). Pdx1 activity is modulated through interactions with various coregulators, including the Swi/Snf chromatin remodeling and Nucleosome Remodeling and Deacetylase (NuRD) complexes. Loss of one Swi/Snf ATPase subunit, Brg1, in early pancreatogenesis reduces final pancreas mass, and β-cell-specific deletion of both subunits, Brg1 and Brm, leads to glucose intolerance and loss of insulin production in the β-cell. Here, we hypothesized Swi/Snf governs endocrine progenitor cell development and postnatal islet function. To test this, we generated conditional murine knockouts of Brg1 (Brg1Δendo;Brm+/-), Brm (Brg1Δendo/+;Brm-/-), or both subunits (DKOΔendo) during endocrine cell development. No DKOΔendo mice were recovered at weaning, and loss of Brg1 but not Brm led to severe glucose intolerance, ad-lib fed hyperglycemia, and reduced insulin levels by four weeks of age. Brg1Δendo;Brm+/- mice had fewer islets and compromised insulin secretion. Together, these data suggest that loss of Brg1 during endocrine cell development has negative impacts on postnatal islet function, with loss of both Brg1 and Brm being early postnatal lethal. Pdx1 has been shown to also interact with the Chd4 helicase subunit of the NuRD complex. Here, we demonstrate Pdx1:Chd4 interactions are increased under stimulatory conditions and hypothesize that Chd4 modulates expression of Pdx1-bound genes critical for β-cell function. To test this, we generated a tamoxifen inducible, β-cell-specific Chd4 knockout mouse model (Chd4Δβ). Four weeks following Chd4 removal, Chd4Δβ mutants were glucose intolerant with severe insulin secretion defects. Additionally, Chd4Δβ islets contained fewer mature insulin granules and secreted more proinsulin. RNA-sequencing from Chd4Δβ β-cells identified numerous upregulated (eg Hk2, Mycl) and downregulated genes (eg MafA, Chga, Chgb, Slc2a2). Through ATAC-sequencing, we discovered several differentially accessible genomic regions, including Chd4-bound and Pdx1-controlled MafA Region 3, which had reduced accessibility in Chd4Δβ β-cells. Lastly, we demonstrate that CHD4 impacts human β-cell function and PDX1:CHD4 interactions were reduced in human donor β-cells with type 2 diabetes, demonstrating loss of these interactions is a significant feature of diabetes pathogenesis.

No description available.

[Truncated abstract] Breast cancer is the cause of significant suffering and death in our community. It is now estimated that the risk of developing breast cancer for an Australian woman before the age of 85 is 1 in 8, with this risk rising for unknown reasons. While mortality rates from breast cancer are falling due to increased awareness and early detection, few new treatments have been developed from an advanced understanding of the molecular basis of the disease. From decades of scientific research it is clear that estrogen (E2) has a large role to play in breast cancer. However, the basic mechanism behind E2 action in breast cancer remains unclear. E2 plays a fundamental role in breast cancer cell proliferation and is highly expressed in breast cancers, thus, it is important to understand both E2 and its receptor, the estrogen receptor (ER). The ER is a member of the nuclear receptor (NR) superfamily. The NR superfamily consists of a large group of proteins which regulate a large number of homeostatic proteins together with regulator proteins termed coregulators and corepressors. SRA (steroid receptor RNA activator) is the only known RNA coactivator and augments transactivation by NRs. SRA has been demonstrated to play an important role in mediating E2 action (Lanz et al., 1999; Lanz et al., 2003) and its expression is aberrant in many human breast tumors, suggesting a potential role in breast tumorigenesis (Murphy et al., 2000). Despite evidence that an alternative splice variant of SRA exists as a protein (Chooniedass-Kothari et al., 2004), it has been conclusively shown that SRA can function as an RNA transcript to coactivate NR transcription (Lanz et al., 1999; Lanz et al., 2002; Lanz et al., 2003). The precise mechanism by which SRA augments ER activity remains unknown. However, it is currently hypothesized that SRA acts as an RNA scaffold for other coregulators at the transcription initiation site. Several SRA stem loops have been identified as important for SRA function, including structure (STR) 1, 5 and 7 (Lanz et al., 2002; Zhao et al., 2007). Previously, I sought to identify SRA-binding proteins using a specific stem-loop structure of SRA (STR7) that was identified as both important for its coactivator function (Lanz et al., 2002) and also as a target for proteins from breast cancer cell extracts (Hatchell, 2002). From a yeast E. Hatchell Abstract iii III hybrid screen using STR7 as bait, I identified a novel protein which was named SLIRP (Patent Number: WO/2007/009194): SRA stem-Loop Interacting RNA-binding Protein (Hatchell, 2002; Hatchell et al., 2006). '...' This thesis demonstrates that SLIRP modulates NR transactivation, provides mechanistic insight into interactions between SRA, SRC-1, HSP-60 and NCoR and suggests that SLIRP may regulate mitochondrial function. These studies contribute significantly to the growing field of NR biology, and contribute more specifically to the elucidation of estrogen action in breast cancer. Furthermore, it lays a strong and exciting foundation for further studies to evaluate SLIRP as a biomarker and potential therapeutic target in hormone dependent cancers.

No description available.